Announcements Trials
Browse Landscape

Status

Recruiting 3Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 3

Study Type

Observational 3

Sponsor

Cancer Type

Tumor-Agnostic 3

Conditions

Uterine Cervical Neoplasms 3Neoplasms 3Glioma 2Glioblastoma 2Breast Neoplasms 2Xeroderma Pigmentosum 1Uterine Cervical Dysplasia 1Trichothiodystrophy Syndromes 1Squamous Intraepithelial Lesions 1Spinal Cord Neoplasms 1Sexuality 1Sarcoma 1Prostatic Neoplasms 1Pilonidal Sinus 1Ovarian Neoplasms 1Neurofibroma 1Meningioma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Ependymoma 1Endometrial Neoplasms 1DNA Repair-Deficiency Disorders 1Cockayne Syndrome 1Cardiovascular Diseases 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Endometrioid 1Breast Carcinoma In Situ 1Breast Cancer Survivors 1Brain Neoplasms 1Bone Neoplasms 1Atypical Squamous Cells of the Cervix 1

Interventions

pembrolizumab 38Blood Specimen Collection 38Bevacizumab 22Surveys and Questionnaires 18Standard of Care 18Radiotherapy 17Exercise 17Carboplatin 17Nivolumab 15atezolizumab 14Paclitaxel 14Cisplatin 14Drug Therapy 13Fluorouracil 12Cyclophosphamide 12Cetuximab 11Trastuzumab 10Pemetrexed 10Leucovorin 10Docetaxel 10Dexamethasone 10Oxaliplatin 9Biopsy 9pertuzumab 8olaparib 8Temozolomide 8Panitumumab 8Observation 8Irinotecan 8abemaciclib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Neoplasms × Restraint, Physical × Clear all
NCT02296450 2025-12-19

Quality of Life (QoL) Assessment in Cancer Patients and Survivors With Dermatologic Conditions Using Dermatologic QoL Instruments

Memorial Sloan Kettering Cancer Center

Recruiting
1,025 enrolled
Tumor-Agnostic

Neoplasms

NCT04732273 2025-09-23

SCCSS-FU

University of Bern

Recruiting
3,000 enrolled
Tumor-Agnostic

Neoplasms

NCT04811794 2022-08-17

Young Survivors at Kantonsspital Aarau, Switzerland

Kantonsspital Aarau

Recruiting
300 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡